Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

CTP-543 is generally safe for treating alopecia areata.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Raltegravir may cause hair loss in some patients.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Tofacitinib may help regrow hair in alopecia areata patients.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Avacopan may cause unexpected side effects, so early monitoring is important.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.

New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.

High-dose interferon is effective for chronic hepatitis C but often causes flu-like symptoms.

Upadacitinib improved multiple immune-related conditions in one patient.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.